All In Biotech

Drug Trial Radar · NCT01172808

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma

Last checked: Nov 19, 2026Latest source record: Jun 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,071 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,071

Actual

Start

Aug 2010

Primary completion

Nov 2012

Study completion Nov 2012

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
Pfizer
First posted
Jul 30, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium over a 24-week treatment period as compared to placebo and salmeterol (50 mcg twice daily). Tiotropium inhalation solution delivered by the Respimat® inhaler will be examined on top of maintenance treatment with inhaled corticosteroid controller medication in patients with moderate persistent asthma. Efficacy and safety will be assessed by measuring effects on lung function, effects on asthma exacerbations, effects on quality of life, effects on asthma control, effects on health care resource utilisation, and number of adverse events.

Conditions

  • Asthma

Interventions

  • PlaceboDrug

    Placebo that represents comparator

  • tiotropium Respimat® low doseDrug

    IMP

  • PlaceboDrug

    Placebo that represents comparator

  • PlaceboDrug

    Placebo that represents comparator

  • tiotropium Respimat® high doseDrug

    IMP

  • 50 mcg salmeterol HFA MDIDrug

    Active comparator

  • PlaceboDrug

    Placebo that represents BI drug

  • PlaceboDrug

    Placebo that represents BI drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak FEV1 Within 3 Hours Post-dose ResponseTime frame: 24 weeks
  2. Trough FEV1 ResponseTime frame: 24 weeks
  3. The Responder Rate as Assessed by the ACQ From the Two Twin Trials 205.419 (NCT01172821) and the Present 205.418 (NCT01172808)Time frame: 24 weeks

Locations

114 sites in 11 countries. Site status is shown where the registry gives one.

  • 205.418.01020 Boehringer Ingelheim Investigational Site

    Huntington Beach, California

  • 205.418.01002 Boehringer Ingelheim Investigational Site

    Mission Viejo, California

  • 205.418.01014 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 205.418.01011 Boehringer Ingelheim Investigational Site

    Wheat Ridge, Colorado

  • 205.418.01004 Boehringer Ingelheim Investigational Site

    Coeur d'Alene, Idaho

  • 205.418.01017 Boehringer Ingelheim Investigational Site

    Normal, Illinois

  • 205.418.01008 Boehringer Ingelheim Investigational Site

    South Bend, Indiana

  • 205.418.01012 Boehringer Ingelheim Investigational Site

    Baltimore, Maryland

  • 205.418.01013 Boehringer Ingelheim Investigational Site

    North Dartmouth, Massachusetts

  • 205.418.01015 Boehringer Ingelheim Investigational Site

    North Dartmouth, Massachusetts

  • 205.418.01009 Boehringer Ingelheim Investigational Site

    Minneapolis, Minnesota

  • 205.418.01006 Boehringer Ingelheim Investigational Site

    Bellevue, Nebraska

  • 205.418.01016 Boehringer Ingelheim Investigational Site

    Boys Town, Nebraska

  • 205.418.01003 Boehringer Ingelheim Investigational Site

    Omaha, Nebraska

  • 205.418.01021 Boehringer Ingelheim Investigational Site

    Winston-Salem, North Carolina

  • 205.418.01018 Boehringer Ingelheim Investigational Site

    Oklahoma City, Oklahoma

  • 205.418.01005 Boehringer Ingelheim Investigational Site

    Charleston, South Carolina

  • 205.418.01010 Boehringer Ingelheim Investigational Site

    Easely, South Carolina

  • 205.418.01007 Boehringer Ingelheim Investigational Site

    Dallas, Texas

  • 205.418.01019 Boehringer Ingelheim Investigational Site

    Seattle, Washington

  • 205.418.01001 Boehringer Ingelheim Investigational Site

    Tacoma, Washington

  • 205.418.55002 Boehringer Ingelheim Investigational Site

    Juiz de Fora, Brazil

  • 205.418.55001 Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • 205.418.55004 Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • 205.418.55005 Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • 205.418.55003 Boehringer Ingelheim Investigational Site

    Rio de Janeiro - RJ, Brazil

  • 205.418.86001 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 205.418.86005 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 205.418.86007 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 205.418.86012 Boehringer Ingelheim Investigational Site

    Beijing, China

  • 205.418.86014 Boehringer Ingelheim Investigational Site

    Changsha, China

  • 205.418.86011 Boehringer Ingelheim Investigational Site

    Chengdu, China

  • 205.418.86015 Boehringer Ingelheim Investigational Site

    Chengdu, China

  • 205.418.86003 Boehringer Ingelheim Investigational Site

    Chongqing, China

  • 205.418.86010 Boehringer Ingelheim Investigational Site

    Guangzhou, China

  • 205.418.86013 Boehringer Ingelheim Investigational Site

    Kunming, China

  • 205.418.86008 Boehringer Ingelheim Investigational Site

    Qingdao, China

  • 205.418.86002 Boehringer Ingelheim Investigational Site

    Shanghai, China

  • 205.418.86004 Boehringer Ingelheim Investigational Site

    Shenyang, China

  • 205.418.86009 Boehringer Ingelheim Investigational Site

    Shenyang, China

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.